Original Articles |
From the From Mid America Heart Institute of Saint Lukes Hospital (S.V.A., C.D., K.J.R., S.G., J.A.S.), Kansas City, Mo; Washington University in St. Louis (S.V.A., G.E.S.), St. Louis, Mo; University of Missouri at Kansas City (C.D., S.M., J.A.S.), Kansas City, Mo; University of Chicago (H.A.), Chicago, Ill; and Childrens Mercy Hospital and Clinics (O.O.), Kansas City, Mo.
Correspondence to John A. Spertus, MD, MPH, Saint Lukes Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111. E-mail spertusj{at}umkc.edu
Received May 12, 2008; accepted June 27, 2008.
| Abstract |
|---|
|
|
|---|
Methods and Results— Between August 2006 and May 2007, patients undergoing nonemergent cardiac catheterization who received the original consent form (n=142) were interviewed and compared with those who received the PREDICT consent form (n=193). Hierarchical modified Poisson regression models were used to adjust for clustering of patients within physicians. Compared with the original consent group, those in the PREDICT group reported higher rates of reading the consent form (72% versus 44%, relative risk [RR] 1.64, 95% confidence interval [CI] 1.24 to 2.16), increased perception of shared decision making (67% versus 45%, RR 1.48, 95% CI 0.99 to 2.22), and decreased anxiety (35% versus 55%, RR 0.70, 95% CI 0.53 to 0.91). Although there were no differences between groups in patients ability to name complications of percutaneous coronary intervention, among patients who identified either death or bleeding as a potential complication, more patients in the PREDICT group recalled being informed of their estimated risk of that complication (death: 85% versus 62%, RR 1.37, 95% CI 1.03 to 1.82; bleeding: 92% versus 71%, RR 1.28, 95% CI 1.06 to 1.56).
Conclusions— In this preliminary, single-center experience, individualized consent forms with patient-specific risks were associated with improved participation in the consent process, reduced anxiety, and better risk recall. PREDICT is one potential strategy for improving the current practice of obtaining informed consent for percutaneous coronary intervention.
Key Words: informed consent angioplasty decision making, shared
| Introduction |
|---|
|
|
|---|
Editorial see p 7
Clinical Perspective p 28
Given the generic legal informed consent documents often used for PCI, the amount and quality of the education patients receive before the procedure depends primarily on undocumented, qualitative aspects of physician-patient discussions, a process that is highly variable. Moreover, at the time of obtaining consent, physicians are charged with the responsibility to inform patients about their risks of complications, which can vary greatly from patient to patient. Because of a lack of viable alternatives, physicians typically provide vague estimations of risk based on their experience and intuition,11 which have been shown to be poor estimates of patients actual risks of complications.12
To overcome the communication barriers surrounding education and risk estimation and to facilitate the process of informed consent, we developed and implemented a World Wide Web–based program, PREDICT (Patient Refined Expectations for Deciding Invasive Cardiac Treatments),13,14 to systematically embed patient-specific estimates of risk, derived from validated preprocedural multivariable models, into individualized PCI consent documents. We also rewrote the consent form to lower its literacy level (from a 16th-grade level to the 8th-grade level) and to provide visual depictions of hard-to-understand terms, such as angiography and stent implantation. These steps sought to transform a perfunctory phase of clinical care into an educational opportunity to better inform patients about their treatment and to enable them to participate more actively in their care.
The goal of PREDICT is to both enhance and standardize the informed consent process before PCI and to permit both patients and physicians to assess estimated complication risks based on clinical evidence rather than intuition. The goal of the present study was to evaluate the patients experiences with the PREDICT consent form compared with the original consent process. As an exploratory analysis, we also investigated the association of PREDICT use with the selection of a drug-eluting stent (DES) or bare-metal stent (BMS). Given that our tool transparently displays the risks of clinical restenosis with each treatment, we anticipated that BMS might be used preferentially in those at low risk for restenosis, for whom the absolute benefits of DES are lower.
| Methods |
|---|
|
|
|---|
The process of generating the individualized consent documents is managed by the nursing staff in the precatheterization holding area. Nurses collect and enter 22 patient characteristics (several of which—including age, sex, and laboratory data—are autopopulated from an HL7 [Health Level Seven] interface with other electronic hospital systems) into the Web-based program, which then creates the patients individualized, evidence-based informed consent document (see Figure 1 for sample consent document). The document is provided to patients for review before they discuss the procedure with the physician and sign the consent form. In the 4 hospitals in the Saint Lukes Health System, interventional cardiologists perform all diagnostic catheterizations with the possibility of PCI during the same procedure. Thus, a single consent document is completed for catheterization with possible PCI, and all discussions about risks and benefits of PCI occur before the diagnostic catheterization.
|
Study Protocol
Patients were interviewed by a nurse or medical student within 48 hours of their procedure in a structured interview (tool available on request). Patients were first asked if they had read the consent form. If they reported having read the form, they were then asked a series of questions, based on a previously validated tool for oncology clinical trials,19 that were designed to judge the ease of reading, ease of comprehension, and anxiety related to the consent document and process. In early 2007, the tool was modified to additionally determine the patients recollection of potential complications from PCI and the estimated risk of those complications occurring. Patients were first asked whether they had had a conversation with the physician about the complications of the procedure. Those patients who reported having had such conversations were asked, in an open-ended question, to list any potential complications of cardiac catheterization. If a patient was able to identify a complication, he or she was then asked what their risk was of that complication occurring. Data on type of stent placed (BMS versus DES) were also collected postprocedurally for all patients who underwent PCI. Institutional Research Board approval was obtained, and a waiver of informed consent was issued.
Statistical Analysis
Clinical and demographic patient characteristics were compared between groups with t tests for continuous variables and
2 or Fisher exact tests for categorical variables, as appropriate. The model-derived estimated risks of complications (Table 1)20 were compared between groups with t tests on the logit scale because of nonnormality of the raw probabilities. Because the quality of informed consent is dependent on the physician who obtains consent from the patient, we used hierarchical modified Poisson regression models to adjust for the clustering of patients within a specific interventional cardiologist (n=12, median cluster size=29 [interquartile range 10 to 37]) who obtained the informed consent and performed the PCI. Typical analyses use logistic regression to estimate adjusted odds ratios, which are then generally interpreted as relative risks (RRs); however, in the present study, the events being modeled were not rare, such that odds ratios were poor estimates of RRs. To address this issue, we estimated adjusted RRs directly using a modified Poisson regression model.21 Results of the surveys are thus presented as physician-adjusted RRs of the outcome of interest if given a PREDICT consent form.
|
The authors had full access to the data and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
The main findings of the study are shown in Tables 2 and 3
. After between-physician variation was considered, nearly twice as many patients reported reading the PREDICT consent form than the original consent form (72% versus 44%; RR 1.64, 95% confidence interval [CI] 1.24 to 2.16, P=0.001). A greater percentage of PREDICT patients reported not feeling nervous at all after reading the enhanced consent form than patients given the original consent form (65% versus 45%; RR 1.43, 95% CI 1.10 to 1.87, P=0.008), and more of them thought the form was easy to understand (61% versus 50%; RR 1.21, 95% CI 1.05 to 1.40, P=0.009). Additionally, there were trends for more patients in the PREDICT group to have felt involved in the decision processes relating to the procedure (67% versus 45%; RR 1.48, 95% CI 0.99 to 2.22, P=0.059) and to be able to report that the descriptions of the complications of PCI were clear (66% versus 53%; RR 1.23 95% CI 1.00 to 1.53, P=0.052; Table 2).
|
|
In an exploratory analysis of stent selection by risk of restenosis, 188 patients underwent PCI with stent placement during the study period, of whom 157 (84%) received a DES. Eight patients were excluded who did not have sufficient data to determine their restenosis risk category. Of the remaining 180 patients who underwent PCI, 54 (30%) were at low risk for stenosis within the following year if treated with a BMS, 71 (39%) were at moderate risk, and 55 (31%) were at high risk for stenosis. Before the implementation of PREDICT,
90% of patients received a DES, regardless of their preprocedural risk of restenosis (Figure 2). After the implementation of PREDICT, patients at low or moderate risk for restenosis were less likely to receive a DES than if they had been given the original consent form (low risk 77% versus 96%, RR 0.80, 95% CI 0.62 to 1.03, P=0.08; moderate risk 61% versus 90%, RR 0.68, 0.53 to 0.88, P=0.004). In contrast, patients at high risk for restenosis continued to experience very high levels of DES use after implementation of the PREDICT consent form compared with the original consent form (91% versus 91%, RR 1.01, 95% CI 0.86 to 1.19, P=0.93; Figure 2). Variation in the effect of PREDICT by physician was examined by augmentation of the base model with an additional physician-level random treatment effect. This did not result in a significantly improved fit (as measured by log-likelihood and Akaike information criterion statistics), and the PREDICT effect estimates, CIs, and probability values were essentially unchanged, which indicates that the effect of PREDICT was largely consistent across physicians.
|
| Discussion |
|---|
|
|
|---|
As previously described, the patient-specific benefits observed in the present study echoed the views of physicians and nurses that the PREDICT informed consent represents an improvement in the processes of care compared with the traditional informed consent documents previously used at our institutions.15 In fact, based on the provider perspective alone, the project was extended from its initial implementation at a single site to deployment throughout the healthcare system. Documentation of the improvements in the informed consent process from the patients perspectives suggests that such individualized consent processes may represent an important advance in clinical care by replacing a perfunctory informed consent process with an opportunity to educate and involve patients in their clinical care.
The current status of the informed consent process, unfortunately, has repeatedly been found to be inadequate in providing patients with the knowledge and skills necessary to actively participate in decisions about their care. A review of 540 informed consent documents from 157 randomly selected US hospitals concluded that the "forms as designed have limited value: they are constructed to authorize treatment or to document an action pertaining to informed consent, regardless of whether the informed consent process was successfully accomplished or of minimal quality."23 In fact, researchers have noted that 69% of patients interviewed after surgery acknowledge not having read the informed consent form.24 Furthermore, truly informed consent requires not only disclosure but also a fundamental understanding of the disclosed information, which has been shown in multiple studies to be severely lacking in current practice. In a study of 100 patients interviewed within days of their surgery, 44 could not provide any details of the procedure, and 27 did not even know which organ had been operated on.25 This suggests that the informed consent process is treated by most providers as simply a legal obligation; however, the opportunity exists to mold the consent process into an important opportunity to educate patients, so that they can become well-informed, responsible, and willing participants in the treatment process.
The results of the present study suggest that PREDICT is a potential strategy for improving the current informed consent process for PCI and can serve as a foundation for better shared decision making. The extent to which individual patients are willing and able to participate in decisions about their care varies greatly26,27; however, prior studies suggest that even in urgent situations, most patients want to understand what is happening to them and what risks are involved in any procedures they are about to undergo.28 PREDICT addresses these needs of the patient in an innovative yet practical manner.
One of the unique advantages of PREDICT is its ability to create individualized consent forms, with the presentation of the risks of the procedure calculated for each individual patient. This method of estimating risks based on validated multivariable models has been shown to be far superior to the estimation of risks based on the intuition of the physicians.29 In so doing, not only do patients have more realistic expectations about the risks going into the procedure, but physicians may also gain access to tools that can guide clinical decisions (eg, if estimated risk of bleeding is high, the physician may elect to use bivalirudin30 or fluoroscopy for vascular puncture). Although many models have been published that can be used to provide estimates of risks of complications, the mathematical complexity of these models has thus far hindered the ability of clinicians to use them in a busy clinical environment. PREDICT provided an avenue for both patients and physicians to readily access the results of such models and to use them in routine care.
Comparison With Other Studies
PREDICT is the first tool of which we are aware that uses computer-generated individualized risks of complications within an actual informed consent document; however, there have been many small studies that have sought to improve the informed consent process through enhancement of the consent document or through the use of multimedia products. Efforts to improve the consent process, including reducing the reading level of the document or providing additional written or verbal information, have been shown to improve satisfaction and decrease anxiety but have not been shown to improve patients understanding of the risks and complications of the procedure.19,31 In 2 trials that compared video-assisted informed consent with traditional methods of consent before cardiac catheterization, the addition of video information decreased anxiety levels, but comprehension and retention of information were not assessed.32,33 A recent trial demonstrated that patients scheduled for elective cardiac catheterization were able to answer questions more accurately about the technical aspects of the procedure immediately after a video presentation, although extended retention of this information was not tested.34 Although these are promising strategies, the complexity of arranging for patients to view videos or to meet with educational counselors has precluded their routine use within the frenetic pace of modern cardiac care.
Moreover, although these interventions focused on improving patient comprehension and understanding, this is not sufficient to achieve truly informed consent. For patients to be able to make informed choices, they need to understand the procedure and also know their individualized risks for complications. Risk-prediction models can help patients and healthcare professionals estimate risks and make informed decisions35 but have not yet been leveraged to enhance the infrastructure for more evidence-based personalized discussions between patients and their providers. Recognizing this, we used a multimodal approach to improve the informed consent process, reducing the reading level of the document, providing visual depictions of hard-to-understand terms, and including patient-specific estimated risks of procedural complications. Through these interventions, we believe we were able to create a document that facilitates a meaningful dialogue between the physician and patient and moves the process of informed consent toward one of shared decision making while not disrupting the routine practice of care.
Study Limitations
Several potential limitations should be considered when one interprets the present study. Because our intervention altered several aspects of the consent form, including changes in the reading level of the consent, the inclusion of educational diagrams, and the use of evidence-based, individualized estimates of risk, we cannot specify which aspect of the new consent was most important in attaining the improvements documented in the present study. Furthermore, given the complexity of creating and deploying a tool such as PREDICT into the practice of obtaining informed consent, we were not able to conduct a randomized clinical trial of the tool within our center. Thus, the present study was designed as "proof of concept" and as a foundation for a larger, multicenter trial that can more fully document the implications of such an approach to informed consent for patients, clinicians, and the healthcare system. The use of a prepost study design could have potentially introduced bias, because assessments of the original consent and PREDICT consent processes were not performed in the same time period. Although the assessment tool was structured to minimize biases, the nurses and medical students who interviewed the patients were aware of the type of consent the patients had received. Moreover, because the nurses and physicians were aware of the changes in the structures and processes of care that accompanied the implementation of PREDICT, they may have altered their attention to the informed consent process. Thus, the observed changes in the present study may not be attributable completely to PREDICT. In addition, the present findings of a more rational use of DES in high-risk patients and a greater use of BMS in lower-risk patients may have been confounded by evolving questions surrounding the safety of DES. However, the fact that we found no change in the high percentage of DES use in patients at high risk for restenosis does suggest that PREDICT was associated with better tailoring of this therapy to those who stand to benefit the most. Because the cost-effectiveness of DES is likely to be increased by focusing its use among patients who stand to benefit the most, a larger study of the use of PREDICT to assist in the allocation of DES is warranted. Regardless of its impact on resource utilization, the present study results do suggest that PREDICT is well received by patients and likely holds a significant positive value for both patients and physicians.
Finally, although the current informed consent document includes estimations of procedural risks, it does not contain risk-adjusted descriptions of benefits or the risks of alternative treatments. Currently, there are few risk-adjustment models of PCI benefits over alternative treatments, and the research community has not embraced a paradigm of sharing the β-coefficients and covariance matrices needed to program PREDICT to execute such models. In addition, although we present risk estimations of complications that we believe hold significant value to patients and physicians, other potential outcomes of PCI may be of interest to patients or physicians, such as less severe bleeding complications or periprocedural myocardial infarction, for which validated risk models have not yet been developed. Thus, opportunities to further improve the current consent document clearly exist. Despite its limitations, we believe that the present study holds significant value because it demonstrates that the translation of risk-prediction models to clinical care can be accomplished in a manner that is useful to patients and clinicians. Further study, however, is needed to understand the full potential of this technology.
Conclusions
In response to well-documented deficiencies in the informed consent process, we have demonstrated that the PREDICT tool can transparently quantify patients risk profiles and improve communication between clinicians and patients undergoing PCI. PREDICT thus accelerates the Institute of Medicines vision for high-quality healthcare, a vision that encourages patients to be the source of control in selecting treatments most aligned with their individual goals and values.1 These preliminary data lay the foundation for a clinical trial to better establish the impact of improved informed consent documents on subsequent care, resource utilization, clinician satisfaction, and, ultimately, patient outcomes. This initial experience should stimulate others to create innovative solutions to improve the process of informed consent.
| Acknowledgments |
|---|
The study was funded by Doris Duke Charitable Foundation Innovations in Clinical Research Award No. 20020310. The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Disclosures
Drs Spertus and Soto have a patent pending on the ePRISM technology from which the PREDICT tool was created but have not yet received the patent, nor have they made any money from the sale or licensing of this project. Dr Spertus owns the copyright to the Seattle Angina Questionnaire. The remaining authors report no conflicts.
| References |
|---|
|
|
|---|
2. Terry PB. Informed consent in clinical medicine. Chest. 2007; 131: 563–568.[CrossRef][Medline]
3. Godwin Y. Do they listen? A review of information retained by patients following consent for reduction mammoplasty. Br J Plast Surg. 2000; 53: 121–125.[CrossRef][Medline]
4. Shurnas PS, Coughlin MJ. Recall of the risks of forefoot surgery after informed consent. Foot Ankle Int. 2003; 24: 904–908.[Medline]
5. Pesudovs K, Luscombe CK, Coster DJ. Recall from informed consent counseling for cataract surgery. J Law Med. 2006; 13: 496–504.[Medline]
6. Vallance JH, Ahmed M, Dhillon B. Cataract surgery and consent; recall, anxiety, and attitude toward trainee surgeons preoperatively and postoperatively. J Cataract Refract Surg. 2004; 30: 1479–1485.[CrossRef][Medline]
7. Saw KC, Wood AM, Murphy K, Parry JR, Hartfall WG. Informed consent: an evaluation of patients understanding and opinion (with respect to the operation of transurethral resection of prostate). J R Soc Med. 1994; 87: 143–144.[Abstract]
8. Holmboe ES, Fiellin DA, Cusanelli E, Remetz M, Krumholz HM. Perceptions of benefit and risk of patients undergoing first-time elective percutaneous coronary revascularization. J Gen Intern Med. 2000; 15: 632–637.[CrossRef][Medline]
9. Whittle J, Conigliaro J, Good CB, Kelley ME, Skanderson M. Understanding of the benefits of coronary revascularization procedures among patients who are offered such procedures. Am Heart J. 2007; 154: 662–668.[CrossRef][Medline]
10. Arnold SV, Rich MW. Informed consent in older patients with acute coronary syndromes offered invasive management. J Am Geriatr Soc. 2008; 56: 368–369.[CrossRef][Medline]
11. Tanenbaum SJ. Knowing and acting in medical practice: the epistemological politics of outcomes research. J Health Polit Policy Law. 1994; 19: 27–44.
12. Dawes RM, Faust D, Meehl PE. Clinical versus actuarial judgment. Science. 1989; 243: 1668–1674.
13. Soto GE, Jones P, Spertus JA. PRISM TM: a Web-based framework for deploying predictive clinical models. Comput Cardiol. 2004; 31: 193–196.
14. Soto GE, Spertus JA. EPOCH and ePRISM: a Web-based translational framework for bridging outcomes research and clinical practice. Comput Cardiol. 2007; 34: 205–208.
15. Decker C, Arnold SV, Olabiyi O, Ahmad H, Gialde E, Luark J, Riggs L, DeJaynes T, Soto GE, Spertus JA. Implementing an innovative consent form: the PREDICT experience. In press.
16. Piper WD, Malenka DJ, Ryan TJ Jr., Shubrooks SJ Jr., O'Connor GT, Robb JF, Farrell KL, Corliss MS, Hearne MJ, Kellett MA Jr., Watkins MW, Bradley WA, Hettleman BD, Silver TM, McGrath PD, O'Mears JR, Wennberg DE; Northern New England Cardiovascular Disease Study Group. Predicting vascular complications in percutaneous coronary interventions. Am Heart J. 2003; 145: 1022–1029.[CrossRef][Medline]
17. Moscucci M, Kline-Rogers E, Share D, O'Donnell M, Maxwell-Eward A, Meengs WL, Kraft P, DeFranco AC, Chambers JL, Patel K, McGinnity JG, Eagle KA. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation. 2001; 104: 263–268.
18. Kettelkamp R, House J, Garg M, Stuart RS, Grantham A, Spertus J. Using the risk of restenosis as a guide to triaging patients between surgical and percutaneous coronary revascularization. Circulation. 2004; 110 (suppl II): II-50–II-54.[Medline]
19. Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, Fairclough D, Habermann T, Schnell L, Quella S, Cella D; Eastern Cooperative Oncology Group. Randomized, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol. 2003; 21: 836–842.
20. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Anginal Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995; 25: 333–341.[Abstract]
21. Zou G. Modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004; 159: 702–706.
22. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Bethesda, Md: Department of Health, Education, and Welfare; 1978.
23. Bottrell MM, Alpert H, Fischbach RL, Emanuel LL. Hospital informed consent for procedure forms: facilitating quality patient-physician interaction. Arch Surg. 2000; 135: 26–33.
24. Lavelle-Jones C, Byrne DJ, Rice P, Cuschieri A. Factors affecting quality of informed consent. BMJ. 1993; 306: 885–890.
25. Byrne DJ, Napier A, Cuschieri A. How informed is signed consent? BMJ (Clin Res Ed). 1988; 296: 839–840.
26. Millard L, Hallett C, Luker K. Nurse-patient interaction and decision-making in care: patient involvement in community nursing. J Adv Nurs. 2006; 55: 142–150.[CrossRef][Medline]
27. Ziebland S, Evans J, McPherson A. The choice is yours? How women with ovarian cancer make sense of treatment choices. Patient Educ Couns. 2006; 62: 361–367.[CrossRef][Medline]
28. Ivarsson B, Larsson S, Lührs C, Sjöberg T. Extended written pre-operative information about possible complications at cardiac surgery: do the patients want to know? Eur J Cardiothorac Surg. 2005; 28: 407–414.
29. Lee KL, Pryor DB, Harrell FE Jr., Califf RM, Behar VS, Floyd WL, Morris JJ, Waugh RA, Whalen RE, Rosati RA. Predicting outcome in coronary disease: statistical models versus expert clinicians. Am J Med. 1986; 80: 553–560.[CrossRef][Medline]
30. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289: 853–863.
31. Stanley BM, Walters DJ, Maddern GJ. Informed consent: how much information is enough? Aust N Z J Surg. 1998; 68: 788–791.[Medline]
32. Philippe F, Meney M, Larrazet F, Ben Abderrazak F, Dibie A, Meziane T, Folliguet T, Delahousse P, Lemoine JF, Laborde F. Effects of video information in patients undergoing coronary angiography. Arch Mal Coeur Vaiss. 2006; 99: 95–101.[Medline]
33. Herrmann KS, Kreuzer H. A randomized prospective study on anxiety reduction by preparatory disclosure with and without video film show about a planned heart catheterization. Eur Heart J. 1989; 10: 753–757.
34. Steffenino G, Viada E, Marengo B, Canale R; Nursing and the Medical Staff of the Cardiac Catheterization Unit. Effectiveness of video-based patient information before percutaneous cardiac interventions. J Cardiovasc Med. 2007; 8: 348–353.
35. Singh M, Rihal CS, Lennon RJ, Spertus J, Rumsfeld JS, Holmes DR Jr. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc. 2007; 82: 701–708.
| Footnotes |
|---|
Related Article
Circ Cardiovasc Qual Outcomes 2008 1: 7-8.
This article has been cited by other articles:
![]() |
E. D. Peterson, J. A. Spertus, D. J. Cohen, M. A. Hlatky, A. S. Go, B. G. Vickrey, J. L. Saver, and P. C. Hinton Vision and Creation of the American Heart Association Pharmaceutical Roundtable Outcomes Research Centers Circ Cardiovasc Qual Outcomes, November 1, 2009; 2(6): 663 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Krumholz Outcomes Research: Myths and Realities Circ Cardiovasc Qual Outcomes, January 1, 2009; 2(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
H. M. Krumholz Circulation: Cardiovascular Quality and Outcomes: Scholarship to Improve Health and Health Care for Patients and Populations Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 1 - 3. [Full Text] [PDF] |
||||
![]() |
S. V. Rao and S. Y.H. Kim Informing the Consent Process Circ Cardiovasc Qual Outcomes, September 1, 2008; 1(1): 7 - 8. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |